Liquidia (NASDAQ:LQDA) Insider Scott Moomaw Sells 20,533 Shares of Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 20,533 shares of the firm’s stock in a transaction on Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $768,550.19. Following the transaction, the insider directly owned 154,514 shares of the company’s stock, valued at $5,783,459.02. This represents a 11.73% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website.

Scott Moomaw also recently made the following trade(s):

• On Monday, December 1st, Scott Moomaw sold 831 shares of Liquidia stock. The stock was sold at an average price of $32.19, for a total transaction of $26,749.89.

Liquidia Trading Up 4.1%

Shares of NASDAQ LQDA opened at $38.09 on Wednesday. Liquidia Corporation has a 1 year low of $11.26 and a 1 year high of $39.29. The company has a debt-to-equity ratio of 6.19, a current ratio of 2.20 and a quick ratio of 1.96. The firm has a 50-day moving average of $32.14 and a 200 day moving average of $25.58. The stock has a market cap of $3.31 billion, a P/E ratio of -26.45, a price-to-earnings-growth ratio of 1.22 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings data on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The business had revenue of $54.34 million for the quarter, compared to analysts’ expectations of $18.86 million. The company’s revenue for the quarter was up 1106.7% on a year-over-year basis. As a group, sell-side analysts expect that Liquidia Corporation will post -1.51 EPS for the current fiscal year.

Analyst Ratings Changes

LQDA has been the subject of a number of recent research reports. Needham & Company LLC lifted their price objective on Liquidia from $36.00 to $52.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Liquidia in a research report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and issued a $49.00 price target on shares of Liquidia in a research note on Friday. Raymond James Financial reissued a “strong-buy” rating and set a $47.00 price objective on shares of Liquidia in a research report on Tuesday, November 4th. Finally, HC Wainwright lifted their target price on shares of Liquidia from $35.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $39.67.

Key Headlines Impacting Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined about 18.1% to ~10.71M shares as of Dec. 31 (about 17.6% of shares outstanding), lowering potential downward pressure from short sellers and reducing immediate squeeze risk.
• Neutral Sentiment: Reported short-interest data for Jan. 12 appears inconsistent (shows 0 shares / NaN change), which looks like a reporting glitch and should be treated as unreliable until corrected.
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average of $37.43 for roughly $2.49M, reducing his direct stake by ~6.0%. SEC Filing – Roger Jeffs
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 for about $1.38M, a ~9.5% reduction in his holding. SEC Filing – Michael Kaseta
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 for about $1.02M, a ~4.5% stake reduction. SEC Filing – Russell Schundler
• Negative Sentiment: Insider Rajeev Saggar sold 21,142 shares at $37.43 (~$791k), cutting his holdings by ~10.7%. SEC Filing – Rajeev Saggar
• Negative Sentiment: Scott Moomaw sold 20,533 shares at $37.43 (~$769k), an ~11.7% reduction in his stake. SEC Filing – Scott Moomaw
• Negative Sentiment: CAO Dana Boyle sold 11,047 shares at $37.43 (~$413k), a ~6.6% reduction. SEC Filing – Dana Boyle
• Negative Sentiment: Insider Jason Adair sold 13,548 shares at $37.43 (~$507k), and Sarah Krepp sold 13,165 shares (~$493k); both reduced holdings by mid-single-digit to high-single-digit percentages. SEC Filing – Jason Adair SEC Filing – Sarah Krepp

Institutional Investors Weigh In On Liquidia

Several large investors have recently bought and sold shares of LQDA. Farallon Capital Management LLC boosted its holdings in shares of Liquidia by 102.1% during the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the last quarter. Vanguard Group Inc. lifted its position in Liquidia by 10.2% during the third quarter. Vanguard Group Inc. now owns 3,961,217 shares of the company’s stock valued at $90,078,000 after purchasing an additional 367,659 shares during the period. Opaleye Management Inc. boosted its holdings in Liquidia by 9.5% in the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after purchasing an additional 215,000 shares during the last quarter. TCG Crossover Management LLC bought a new stake in Liquidia in the 3rd quarter worth approximately $38,887,000. Finally, Caprock Group LLC purchased a new stake in Liquidia during the 3rd quarter valued at $37,114,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).